Company Overview - West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services, supporting both established and emerging drug developers [4] - The company has over 10,000 team members across 50 sites, including 25 manufacturing facilities worldwide, delivering over 41 billion components and devices each year [4] Financial Performance - In fiscal year 2024, West generated $2.89 billion in net sales [5] - The company is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index [5] Upcoming Events - West will release its first-quarter financial results before the market opens on April 24, 2025, followed by a conference call at 9:00 a.m. Eastern Time [1] - A slide presentation will be available on the company's website on the day of the call, and a replay of the conference call and webcast will be accessible for approximately 90 days after the event [3]

I have not written anything related to West Pharmaceutical Services (NYSE: WST ) since May of 2024. Since then, the company has had a lumpy year. The underperformance against the index has been evident. In this article, I will try toQuality Growth Investor. I have the simplest of tastes, I only like the best. Here I will analyze the companies in my investment universe. I am looking for the best businesses in the world in order to create a long term portfolio that can outperform the market.Analyst’s Disclosu ...

EXTON, Pa., Feb. 20, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2025 dividend of $0.21 per share. The dividend will be paid on May 7, 2025, to shareholders of record as of April 30, 2025.About West  West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a t ...

Customer Concentration - The company's ten largest customers accounted for 43.4% of consolidated net sales in 2024, with one customer contributing 12.3% or $356.4 million[34] - The company reported that its ten largest customers accounted for 43.4% of consolidated net sales in 2024, with one customer contributing 12.3% or $356.4 million[34] Intellectual Property Development - In 2024, more than 170 utility and design patents were issued globally, indicating a strong focus on intellectual property development[27] - In 2024, the company was issued more than 170 utility and design patents globally, indicating a strong focus on intellectual property development[27] Employee Statistics - Approximately 10,600 employees were employed as of December 31, 2024, with an attrition rate of approximately 17% during the year[43] - The company employed approximately 10,600 people as of December 31, 2024, with an attrition rate of approximately 17% during the year[43] - The company has a global gender demographic of 63% men and 37% women among its employees as of December 31, 2024[43] - The company has a global gender demographic of 63% men and 37% women among its employees as of December 31, 2024[43] Supply Chain Management - The company has implemented a supply chain management strategy that relies on single-source suppliers for many critical raw materials, increasing supply chain risk[25] - The company has a supply chain management strategy that relies on single-source suppliers for many critical raw materials, which increases supply chain risk[25] Regulatory Compliance - Compliance with government regulations did not require material capital expenditures in 2024 and is not expected to impact 2025 significantly[29] - The company has not incurred material capital expenditures for compliance with government regulations in 2024 and does not expect significant expenditures in 2025[29] Strategic Initiatives - The company continues to pursue strategic initiatives in drug containment components and integrated drug delivery systems, focusing on innovation and market expansion[42] - The company continues to pursue strategic initiatives in drug containment components and integrated drug delivery systems, focusing on innovation and partnerships[42] Environmental, Social, and Governance (ESG) - The company is committed to enhancing its Environmental, Social, and Governance (ESG) framework, focusing on sustainability and compliance with regulatory requirements[50] - The company has committed to a climate and greenhouse gas reduction strategy, focusing on renewable energy and reducing emissions[50] Employee Retention and Rewards - The company has a comprehensive total rewards program aimed at attracting and retaining high-performing team members, reflecting the value of their contributions[47] - The company has a comprehensive total rewards program aimed at attracting and retaining high-performing team members[47] Health, Safety, and Wellness - The company maintains a strong focus on health, safety, and wellness, with dedicated teams at each manufacturing location to ensure compliance and safety[48]

Group 1 - Robert F. Abbott has been managing family investments since 1995 and incorporated options trading in 2010, focusing on covered calls and collars with long stocks [1] - Abbott is a freelance writer with a project aimed at providing information for new and intermediate-level mutual fund investors [1] - He holds a Bachelor of Arts and a Master of Business Administration (MBA) degree [1]

UKRAINE - 2021/02/08: In this photo illustration a West Pharmaceutical Services logo seen on a ... [+] mobile phone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesWest Pharmaceutical Services, a global provider of solutions for drugs, biologics, gene therapies, and consumer healthcare products, recently announced its Q4 results, surpassing analysts' expectations for both revenue and earnings. The company reported sales o ...

Fourth Quarter Overall Net Sales $748.8M | 2.3% Diluted Earnings Per Share: $1.78 Adjusted Diluted Earnings Per Share: $1.82 "I am pleased to report we had a strong quarter with revenues and profits exceeding our expectations, and a return to positive organic growth as the impact of destocking continues to moderate. Our core businesses continue to benefit from our market-leading positions and proprietary processes. Looking ahead to 2025, we expect our business momentum to continue in key areas of our Propri ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2024 Earnings Conference Call February 13, 2025 9:00 AM ET Company Participants John Sweeney - Vice President of Investor Relations Eric Green - Chairman, President & Chief Executive Officer Bernard Birkett - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - BofA Global Research Lawrence Solow - CJS Securities Patrick Donnelly - Citigroup Inc. Paul Knight - KeyBanc Capital Markets Matthew Larew - William Blair & Com ...

Core Viewpoint - West Pharmaceutical Services reported quarterly earnings of $1.82 per share, exceeding the Zacks Consensus Estimate of $1.75 per share, although down from $1.83 per share a year ago, indicating a 4% earnings surprise [1] Financial Performance - The company achieved revenues of $748.8 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.25%, compared to $732 million in the same quarter last year [2] - Over the last four quarters, West Pharmaceutical has exceeded consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance and Outlook - West Pharmaceutical shares have declined approximately 1.6% since the beginning of the year, while the S&P 500 has gained 2.9% [3] - The company's current consensus EPS estimate for the upcoming quarter is $1.63 on revenues of $715.32 million, and for the current fiscal year, it is $7.44 on revenues of $3.03 billion [7] Industry Context - The Medical - Dental Supplies industry, to which West Pharmaceutical belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, which may impact stock performance [8]

Sales Performance - Fourth-quarter 2024 net sales increased to $748.8 million, a 2.3% increase year-over-year, with organic net sales growth of 3.3%[6] - Full-year 2024 net sales were $2.893 billion, a decline of 1.9%, while organic net sales declined by 1.5%[9] - Fourth-quarter 2024 net sales for the Proprietary Products segment increased to $613.9 million, with organic net sales growth of 4.5%[3] - For the three months ended December 31, 2024, consolidated total net sales were $748.8 million, a 2.4% increase from $732.0 million in the same period of 2023[21] - Organic net sales for the three months ended December 31, 2024, were $756.0 million, reflecting a positive impact from currency translation rates[25] Earnings Per Share (EPS) - Fourth-quarter 2024 reported-diluted EPS was $1.78, a decline of 2.7%, and adjusted-diluted EPS was $1.82, a decline of 0.5%[6] - Full-year 2024 adjusted-diluted EPS was $6.75, a decline of 16.5% compared to the previous year[9] - Reported diluted EPS for the twelve months ended December 31, 2024, was $6.69, with guidance for 2025 projected between $5.97 and $6.17, indicating a potential decrease of 10.8% to 7.8%[26] - Full-year 2025 adjusted-diluted EPS is expected to be in the range of $6.00 to $6.20, including an estimated headwind of approximately $0.23 from foreign currency exchange rates[11] Cash Flow and Capital Expenditures - Operating cash flow for full-year 2024 was $653.4 million, a decline of 15.9%, while free cash flow decreased by 33.3% to $276.4 million[10] - Operating cash flow for the twelve months ended December 31, 2024, was $653.4 million, down from $776.5 million in 2023[29] - Capital expenditures for full-year 2025 are expected to be $275 million, supporting capacity expansions and investments in Contract Manufacturing facilities[11] - Capital expenditures for the twelve months ended December 31, 2024, were $377.0 million, compared to $362.0 million in 2023[29] Profitability Metrics - Gross profit for the twelve months ended December 31, 2024, was $998.5 million, down 11.5% from $1,129.2 million in 2023, resulting in a gross profit margin of 34.5% compared to 38.3%[21] - Adjusted operating profit for the three months ended December 31, 2024, was $162.8 million, reflecting a 1.8% increase from $159.9 million in the same period of 2023[22] Restructuring and Working Capital - The company recorded a restructuring expense of $3.0 million for the three months ended December 31, 2024, related to optimizing its legal structure[23] - Working capital as of December 31, 2024, was $987.7 million, down from $1,264.6 million in 2023[31] Market Performance - The Biologics market unit experienced high-single digit organic net sales growth, driven by self-injection device platforms[4]